Horizon Therap Us Drug Patent Portfolio
Horizon Therap Us owns 1 orange book drug protected by 17 US patents Given below is the list of Horizon Therap Us's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8404215 | Methods of therapeutic monitoring of nitrogen scavenging | 09 Mar, 2032 | Active |
| US9095559 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 09 Mar, 2032 | Active |
| US10045958 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10045959 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10183002 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10183003 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10183004 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10183005 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10183006 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US10668040 | Treatment of urea cycle disorders in neonates and infants | 22 Sep, 2030 | Active |
| US8642012 | Methods of treatment using ammonia-scavenging drugs | 22 Sep, 2030 | Active |
| US9254278 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US9326966 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US9561197 | Methods of therapeutic monitoring of phenylacetic acid prodrugs | 22 Sep, 2030 | Active |
| US9962359 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US9999608 | Methods of therapeutic monitoring of nitrogen scavenging drugs | 22 Sep, 2030 | Active |
| US5968979 | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders | 07 Feb, 2015 | Expired |
Latest Legal Activities on Horizon Therap Us's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Horizon Therap Us.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Nov, 2023 | US10668040 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Oct, 2023 | US9326966 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Aug, 2023 | US9254278 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Feb, 2023 | US9095559 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jul, 2022 | US10183005 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jul, 2022 | US10183002 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jul, 2022 | US10183004 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jul, 2022 | US10183006 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jul, 2022 | US10183003 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2022 | US10045958 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2022 | US10045959 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2021 | US9999608 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Nov, 2021 | US9962359 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Aug, 2021 | US8642012 (Litigated) |
| Review Certificate Mailed | 09 Feb, 2021 | US9095559 (Litigated) |
Horizon Therap Us's Drug Patent Litigations
Horizon Therap Us's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 04, 2015, against patent number US8404215. The petitioner , challenged the validity of this patent, with None as the respondent. Click below to track the latest information on how companies are challenging Horizon Therap Us's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9561197 | August, 2018 |
Terminated-Settled
(24 Oct, 2018)
| Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9095559 | July, 2017 |
Terminated-Settled
(05 Oct, 2018)
| Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9254278 | July, 2017 |
Terminated-Settled
(05 Oct, 2018)
| Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9326966 | July, 2017 |
Terminated-Settled
(05 Oct, 2018)
| Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9254278 | March, 2017 |
Terminated-Settled
(26 Jul, 2018)
| Horizon Therapeutics, LLC | Lupin Ltd. |
| US9326966 | March, 2017 |
Terminated-Settled
(26 Jul, 2018)
| Horizon Therapeutics, LLC | Lupin Ltd. |
| US9561197 | January, 2018 |
Terminated-Settled
(25 Jul, 2018)
| Horizon Therapeutics, LLC | Lupin, Ltd. |
| US9095559 | April, 2016 |
FWD Entered
(26 Sep, 2017)
| Horizon Therapeutics, Inc. | Lupin Ltd |
| US8642012 | April, 2015 |
FWD Entered
(03 Nov, 2016)
| Horizon Therapeutics, Inc. | Par Pharmaceutical, Inc. |
| US8642012 | December, 2015 |
FWD Entered
(03 Nov, 2016)
| ||
| US8404215 | April, 2015 |
FWD Entered
(29 Sep, 2016)
| Horizon Therapeutics, Inc. | Par Pharmaceutical, Inc. |
| US8404215 | December, 2015 |
FWD Entered
(29 Sep, 2016)
| ||
Horizon Therap Us's Family Patents
Horizon Therap Us drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 30.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Horizon Therap Us Drug List
Given below is the complete list of Horizon Therap Us's drugs and the patents protecting them.
1. Ravicti
Ravicti is protected by 17 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8404215 | Methods of therapeutic monitoring of nitrogen scavenging |
09 Mar, 2032
(7 years from now)
| Active |
| US9095559 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
09 Mar, 2032
(7 years from now)
| Active |
| US10045958 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10045959 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10183002 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10183003 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10183004 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10183005 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10183006 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US10668040 | Treatment of urea cycle disorders in neonates and infants |
22 Sep, 2030
(5 years from now)
| Active |
| US8642012 | Methods of treatment using ammonia-scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US9254278 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US9326966 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US9561197 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
22 Sep, 2030
(5 years from now)
| Active |
| US9962359 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US9999608 | Methods of therapeutic monitoring of nitrogen scavenging drugs |
22 Sep, 2030
(5 years from now)
| Active |
| US5968979 | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
07 Feb, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ravicti's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List